Company Description
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses.
It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies.
The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Dec 17, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Jason Okazaki |
Contact Details
Address: Two Tower Place, 7th Floor South San Francisco, California 94080 United States | |
| Phone | 833 509 4583 |
| Website | assemblybio.com |
Stock Details
| Ticker Symbol | ASMB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001426800 |
| CUSIP Number | 045396108 |
| ISIN Number | US0453962070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jason A. Okazaki J.D. | Chief Executive Officer, President and Director |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
| Jeanette M. Bjorkquist | Principal Financial Officer, Executive Director of Accounting and Treasury |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs and Alliance Management |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer |
| Katie Kitrinos | Senior Vice President of Preclinical Research and Development |
| Thomas E. Rollins | Executive Officer |
| Amy Figueroa C.F.A. | Investor Relations Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 19, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2026 | 10-K | Annual Report |
| Mar 19, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13G/A | Filing |
| Dec 8, 2025 | 8-K | Current Report |
| Dec 8, 2025 | SCHEDULE 13G | Filing |
| Nov 21, 2025 | EFFECT | Notice of Effectiveness |
| Nov 21, 2025 | 424B3 | Prospectus |
| Nov 10, 2025 | 10-Q | Quarterly Report |